Inscrição YC de Altay Therapeutics

Winter 2020Active

Altay Therapeutics passou pela Y Combinator no batch Winter 2020 como uma empresa Healthcare. Abaixo: o que a empresa faz, quem a fundou e sua inscrição para a YC, reconstruída pergunta por pergunta no formulário real da YC.

Batch YC: Winter 2020
Indústria: HealthcareTherapeutics
Tamanho da equipe: 6
Status: Active
Lançada: 2020

Fundadores

Ali OzesFounder
Osman OzesFounder

O que Altay Therapeutics faz

Altay develops small molecule drugs to treat chronic liver diseases like liver fibrosis and liver cancer. Our co-founder Dr. Osman Ozes, led the first drug development program for Esbriet (Pirfenidone), resulting in the first FDA approved therapy for lung fibrosis. Esbriet is now a $1 billion/year drug and has already made over $6 billion in revenue. With a team that has over 70+ years of small molecule drug development experience, we intend to do the same with chronic liver diseases, which affects over 20 million Americans and represents a market size of over $30 billion. We know we are well positioned for success because we have shown excellent pre-clinical mouse data in several liver fibrosis models using our novel small molecule. We demonstrate a reduction in fibrosis with our drug, but more significantly, we show a reversal in fibrotic tissue back to normal tissue. With our current developmental strategy, we hope to have a clinic-ready compound by the end of 2021 and be in phase I clinical trials by mid of 2022.

Inscrição YC de Altay Therapeutics, reconstruída

Inscrição Y Combinator

Altay Therapeutics, lote Winter 2020. As verdadeiras perguntas do formulário, respondidas com dados públicos.

Founders2
Company7
Progress7
Idea4
Equity3
Curious2
Batch Preference1

Company

Company name

Altay Therapeutics

Describe what your company does in 50 characters or less.

Small molecule therapies for liver disease

What is your company going to make? Please describe your product and what it does or will do.

We develop small molecule drugs that target transcription pathways to treat chronic liver diseases like fibrosis and cancer. Our lead compound has shown in mouse models not just reduction but reversal of liver fibrosis, aiming for a clinic-ready drug by end of 2021 and phase I trials mid-2022.

Where do you live now, and where would the company be based after YC?

We live and work in San Francisco and South San Francisco, CA, which will remain our base after YC.

Explain your decision regarding location.

We chose to base the company in San Francisco because that's where the biotech innovation ecosystem and our team are. It keeps us close to partners, investors, and talent relevant to small molecule therapeutic development.

21 respostas a mais na inscrição completa

Founders, Progress, Idea, Equity, Curious, Batch Preference estão na versão completa. Crie uma conta gratuita para abri-la no YC Insights, ao lado de todos os outros batches da YC.

Ver inscrição completa

Perguntas Frequentes

Esta é a inscrição real da YC de Altay Therapeutics?

Não. A Y Combinator mantém as inscrições submetidas em privado. Esta é uma reconstrução: as perguntas reais do formulário da YC, respondidas a partir dos dados públicos de Altay Therapeutics (notas de lançamento, históricos de fundadores, descrição do produto). Mostra como uma empresa como Altay Therapeutics se apresentaria à YC, não o texto que eles submeteram.

Em qual batch da YC Altay Therapeutics esteve?

Altay Therapeutics fez parte do batch Winter 2020 da Y Combinator.

Quem fundou o Altay Therapeutics?

O Altay Therapeutics foi fundado por Ali Ozes, Osman Ozes.

O que o Altay Therapeutics faz?

Altay develops disease-modifying therapies targeting transcription…

Como eu leio o application completo reconstruído?

Crie uma conta gratuita no Round Funded. A versão completa de 26 respostas do application do Altay Therapeutics, e de todos os outros lotes do YC, está no YC Insights.